This video discusses the 2-year results from an observant plan treatment regimen designed to alleviate the clinical burden of neovascular age-related macular degeneration (nAMD) (Saturday 10 September 2016, 08:00-09:30). The prospective case series which looked at 112 eyes with naïve neovascular AMD reviewed the disease reoccurrence following three loading fixed doses of aflibercept determined by observational monthly visits. Periodic adjustments of the injection intervals ranged from 1-3 months, and if no disease reoccurrence was observed after 3 months the patient could change to monitoring alone. Main visual acuity improved by +8.5 (SD 9.2), 8.0 (SD 12.0) and 6.2 (SD 14.6) letters at months 3, 12 and 24 respectively. The mean number of injections was 8.7 and 6.5 during the first and second year, and the mean number of ophthalmic examinations was 3.8 and 2.8 during the first and second year respectively. The study demonstrated that observant plan regimen significantly improves visual acuity over the course of 2 years. This favorable functional outcome was achieved with fewer clinical visits and similar number of injections compared with other regimens, therefore observant plan regimens have the potential to alleviate the clinical burden of neovascular AMD.

Related Articles